Correction - Interim report January


Interim report January - June 2010

  * The Group's sales for the period amounted to SEK 265 (333) million.
  * EBITDA amounted to SEK 27 (54) million.
  * Operating profit totalled SEK -9* (43) million.
  * The net profit after tax for the period amounted to SEK -34* (15) million
  * Earnings per share after tax for the period were SEK -0.11 (0.04 ) before
    and after dilution

Significant events during the period

  * I mpairment of SEK 24 million on intangible assets and SEK 7 million on
    inventories.
  * Niklas Prager elected as the new Chairman of the Board of BioPhausia.
  * BioPhausia becomes the main supplier of parallel-imported pharmaceuticals to
    Apoteksgruppen.

Significant events after the period

  * Maris Hartmanis has taken up the position of new BioPhausia CEO on 9 August.
  * The Board has decided to streamline operations and focus on the Nordic
    region.

Period April - June

  * The Group's sales for the period amounted to SEK 134 (153) million.
  * EBITDA amounted to SEK 9 (26) million.
  * Operating profit totalled SEK -20* (20) million.
  * The net profit after tax for the period amounted to SEK -35* (6) million
  * Earnings per share after tax for the period were SEK -0.10 (0.02 ) before
    and after dilution

*Includes one-off costs: impairment of intangible assets, SEK 24 million,
impairment of inventories, SEK 7 million, and costs associated with the change
of CEO, SEK 4 million (SEK 1 million in Q2).



[HUG#1441310]
Correction - Interim report January - June 2010

Attachments
